Phospholipid Ether Boronic Esters for Selective Cancer Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as radiation therapy and boron neutron capture therapy, face challenges in specifically targeting cancer cells while minimizing damage to healthy tissues due to non-specific targeting and toxicity issues.
Innovation Solution
The development of boronic esters of phospholipid ether analogs, which can be used in conjunction with radiation therapy to selectively target and accumulate in cancer cells, allowing for precise delivery of radiation to tumor sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation therapy is used to treat cancer, then cancer cells can be killed, but healthy tissues are also damaged due to non-specific targeting
Solution Approach 1:
The patent uses boron-containing compounds as intermediaries that selectively accumulate in cancer cells before radiation therapy. These compounds serve as a mediator between the radiation source and cancer cells, enabling selective targeting. The boron compounds are taken up by cancer cells through their abnormal metabolism and are retained there, while healthy tissues show minimal uptake. When neutron radiation is applied, the boron-10 nuclei capture neutrons and undergo fission, releasing alpha particles that destroy only the cancer cells containing boron, sparing healthy tissues.
Solution Approach 2:
The patent achieves local quality by creating a non-uniform distribution of boron compounds throughout the body, with high concentration in cancer cells and low concentration in healthy tissues. This spatial variation in boron concentration enables localized radiation effect. The abnormal metabolic pathways of cancer cells are exploited to concentrate boron specifically in tumor regions, creating a quality difference that allows selective destruction of cancer cells while preserving healthy tissues during neutron capture therapy.
2Measurement precision
If boron neutron capture therapy is used to specifically target cancer cells, then radiation can be delivered precisely to tumors, but the complexity of the treatment increases
Solution Approach 1:
The patent applies preliminary action by administering boron-containing compounds to the patient before the neutron radiation therapy. This preliminary step allows the boron compounds to accumulate in cancer cells through their abnormal metabolism and be retained there. The boron compounds are injected systemically and selectively concentrate in tumor tissues over time, creating a pre-positioned target for the subsequent neutron radiation. This preliminary accumulation phase simplifies the overall treatment by eliminating the need for complex real-time targeting systems during radiation delivery.
3Reliability
If conventional radiation therapy is administered, then cancer cells can be destroyed, but the radiation dose cannot be selectively delivered to metastatic cells
Solution Approach 1:
The patent achieves universality by using boron-containing compounds that can target all cancer cells regardless of their location or metastatic status. The boron compounds exploit the universal abnormal metabolic characteristics of cancer cells (such as altered phospholipid metabolism) to accumulate selectively in all malignant tissues throughout the body. This multi-functional approach allows a single compound to target primary tumors, metastatic lesions, and circulating tumor cells uniformly, providing versatile cancer cell destruction capability across all disease sites without requiring different targeting strategies for different metastatic locations.
Data Source
AI summary
The present invention discloses boronic acids and esters of phospholipid ether analogs and methods for their synthesis and use. The boronic acids and esters of phospholipid ether analogs described herein can be used in treating cancer and in particular can be used in conjunction with radiation therapy, such as external beam radiation therapy and neutron capture therapy to specifically target and kill cancer cells.